{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:03Z","timestamp":1790014683055,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nagoya University Medical Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Studies over recent years have redeveloped our understanding of uremic cardiomyopathy, defined as left ventricular hypertrophy, congestive heart failure, and associated cardiac hypertrophy plus other abnormalities that result from chronic kidney disease and are often the cause of death in affected patients. Definitions of uremic cardiomyopathy have conflicted and overlapped over the decades, complicating the body of published evidence, and making comparison difficult. New and continuing research into potential risk factors, including uremic toxins, anemia, hypervolemia, oxidative stress, inflammation, and insulin resistance, indicates the increasing interest in illuminating the pathways that lead to UC and thereby identifying potential targets for intervention. Indeed, our developing understanding of the mechanisms of UC has opened new frontiers in research, promising novel approaches to diagnosis, prognosis, treatment, and management. This educational review highlights advances in the field of uremic cardiomyopathy and how they may become applicable in practice by clinicians. Pathways to optimal treatment with current modalities (with hemodialysis and angiotensin-converting enzyme inhibitors) will be described, along with proposed steps to be taken in research to allow evidence-based integration of developing investigational therapies.<\/jats:p>","DOI":"10.1007\/s10741-023-10318-1","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T20:02:11Z","timestamp":1683921731000},"page":"1129-1139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Implications of uremic cardiomyopathy for the practicing clinician: an educational review"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-7037","authenticated-orcid":false,"given":"Hiroaki","family":"Hiraiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-3003","authenticated-orcid":false,"given":"Daisuke","family":"Kasugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-2052","authenticated-orcid":false,"given":"Takahiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-6243","authenticated-orcid":false,"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"2","key":"10318_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00059-019-04884-0","volume":"45","author":"T Saritas","year":"2020","unstructured":"Saritas T, Floege J (2020) Cardiovascular disease in patients with chronic kidney disease. Herz 45(2):122\u2013128. https:\/\/doi.org\/10.1007\/s00059-019-04884-0","journal-title":"Herz"},{"issue":"2","key":"10318_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000111829","volume":"28","author":"M Chonchol","year":"2008","unstructured":"Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR (2008) Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 28(2):354\u2013360. https:\/\/doi.org\/10.1159\/000111829","journal-title":"Am J Nephrol"},{"issue":"5","key":"10318_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ki.1979.170","volume":"16","author":"SG Rostand","year":"1979","unstructured":"Rostand SG, Gretes JC, Kirk KA, Rutsky EA, Andreoli TE (1979) Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 16(5):600\u2013611. https:\/\/doi.org\/10.1038\/ki.1979.170","journal-title":"Kidney Int"},{"issue":"4","key":"10318_CR4","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1111\/chf.12030","volume":"19","author":"E Alhaj","year":"2013","unstructured":"Alhaj E, Alhaj N, Rahman I, Niazi TO, Berkowitz R, Klapholz M (2013) Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Failure 19(4):E40\u2013E50. https:\/\/doi.org\/10.1111\/chf.12030","journal-title":"Congest Heart Failure"},{"issue":"17","key":"10318_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/heartjnl-2019-315138","volume":"105","author":"A Radhakrishnan","year":"2019","unstructured":"Radhakrishnan A, Pickup LC, Price AM et al (2019) Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy? Heart 105(17):1302\u20131309. https:\/\/doi.org\/10.1136\/heartjnl-2019-315138","journal-title":"Heart"},{"issue":"2","key":"10318_CR6","doi-asserted-by":"publisher","first-page":"c47","DOI":"10.1159\/000086221","volume":"101","author":"K Kundhal","year":"2005","unstructured":"Kundhal K, Lok CE (2005) Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 101(2):c47\u2013c52. https:\/\/doi.org\/10.1159\/000086221","journal-title":"Nephron Clin Pract"},{"issue":"13","key":"10318_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031.Erratum.In:NEnglJMed.2008;18(4):4","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031.Erratum.In:NEnglJMed.2008;18(4):4","journal-title":"N Engl J Med"},{"issue":"10","key":"10318_CR8","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/sj.ki.5000249","volume":"69","author":"PB Mark","year":"2006","unstructured":"Mark PB, Johnston N, Groenning BA et al (2006) Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69(10):1839\u20131845. https:\/\/doi.org\/10.1038\/sj.ki.5000249","journal-title":"Kidney Int"},{"issue":"7","key":"10318_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1681\/asn.v1071606","volume":"10","author":"PS Parfrey","year":"1999","unstructured":"Parfrey PS, Foley RN (1999) The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10(7):1606\u20131615. https:\/\/doi.org\/10.1681\/asn.v1071606","journal-title":"J Am Soc Nephrol"},{"key":"10318_CR10","doi-asserted-by":"publisher","first-page":"117954682199834","DOI":"10.1177\/1179546821998347","volume":"15","author":"K Garikapati","year":"2021","unstructured":"Garikapati K, Goh D, Khanna S, Echampati K (2021) Uraemic cardiomyopathy: a review of current literature. Clin Med Insights Cardiol 15:1179546821998347. https:\/\/doi.org\/10.1177\/1179546821998347","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"10318_CR11","first-page":"263","volume":"13","author":"GL Bailey","year":"1967","unstructured":"Bailey GL, Hampers CL, Merrill JP (1967) Reversible cardiomyopathy in uremia. ASAIO J 13(1):263\u2013270","journal-title":"ASAIO J"},{"issue":"3","key":"10318_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","volume":"15","author":"X Wang","year":"2019","unstructured":"Wang X, Shapiro JI (2019) Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol 15(3):159\u2013175. https:\/\/doi.org\/10.1038\/s41581-018-0101-8","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10318_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jcmg.2013.09.025","volume":"7","author":"NC Edwards","year":"2014","unstructured":"Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP (2014) Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging 7(7):703\u2013714. https:\/\/doi.org\/10.1016\/j.jcmg.2013.09.025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10318_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1681\/ASN.2011111115","volume":"23","author":"MM Mitsnefes","year":"2012","unstructured":"Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23(4):578\u2013585. https:\/\/doi.org\/10.1681\/ASN.2011111115","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10318_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MNH.0000000000000684","volume":"30","author":"AM Kouri","year":"2021","unstructured":"Kouri AM, Rheault MN (2021) Cardiovascular disease in children with chronic kidney disease. Curr Opin Nephrol Hypertens 30(2):231\u2013236. https:\/\/doi.org\/10.1097\/MNH.0000000000000684","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"12","key":"10318_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrneph.2015.140","volume":"11","author":"N Nicolaou","year":"2015","unstructured":"Nicolaou N, Renkema KY, Bongers EM, Giles RH, Knoers NV (2015) Genetic, environmental, and epigenetic factors involved in CAKUT. Nat Rev Nephrol 11(12):720\u2013731. https:\/\/doi.org\/10.1038\/nrneph.2015.140","journal-title":"Nat Rev Nephrol"},{"issue":"3 Suppl 1","key":"10318_CR17","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1053\/ajkd.2003.50099","volume":"41","author":"G Bellinghieri","year":"2003","unstructured":"Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V (2003) Carnitine and hemodialysis. Am J Kidney Dis 41(3 Suppl 1):S116\u2013S122. https:\/\/doi.org\/10.1053\/ajkd.2003.50099","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10318_CR18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/ki.2015.305","volume":"88","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Zhang L, Mitch WE (2015) Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int 88(6):1233\u20131239. https:\/\/doi.org\/10.1038\/ki.2015.305","journal-title":"Kidney Int"},{"issue":"8","key":"10318_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41581-022-00576-x","volume":"18","author":"N Patel","year":"2022","unstructured":"Patel N, Yaqoob MM, Aksentijevic D (2022) Cardiac metabolic remodelling in chronic kidney disease. Nat Rev Nephrol 18(8):524\u2013537. https:\/\/doi.org\/10.1038\/s41581-022-00576-x","journal-title":"Nat Rev Nephrol"},{"key":"10318_CR20","doi-asserted-by":"publisher","unstructured":"Br\u00f8nnum H, Kalluri R (2012) Chapter 29 \u2013 Cardiac fibrosis: cellular and molecular determinants. Muscle 1:389\u2013404. https:\/\/doi.org\/10.1016\/B978-0-12-381510-1.00029-6","DOI":"10.1016\/B978-0-12-381510-1.00029-6"},{"issue":"3\u20134","key":"10318_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000369817","volume":"128","author":"B Lisowska-Myjak","year":"2014","unstructured":"Lisowska-Myjak B (2014) Uremic toxins and their effects on multiple organ systems. Nephron Clin Pract 128(3\u20134):303\u2013311. https:\/\/doi.org\/10.1159\/000369817","journal-title":"Nephron Clin Pract"},{"issue":"9","key":"10318_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/toxins11090529","volume":"11","author":"L H\u00e9naut","year":"2019","unstructured":"H\u00e9naut L, Candellier A, Boudot C et al (2019) New insights into the roles of monocytes\/macrophages in cardiovascular calcification associated with chronic kidney disease. Toxins (Basel) 11(9):529. https:\/\/doi.org\/10.3390\/toxins11090529","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10318_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/MNH.0000000000000231","volume":"25","author":"A Grabner","year":"2016","unstructured":"Grabner A, Faul C (2016) The role of fibroblast growth factor 23 and klotho in uremic cardiomyopathy. Curr Opin Nephrol Hypertens 25(4):314\u2013324. https:\/\/doi.org\/10.1097\/MNH.0000000000000231","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10318_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584\u2013592. https:\/\/doi.org\/10.1056\/NEJMoa0706130","journal-title":"N Engl J Med"},{"issue":"5","key":"10318_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1681\/ASN.2014040325","volume":"26","author":"J Xie","year":"2015","unstructured":"Xie J, Yoon J, An SW, Kuro-o M, Huang CL (2015) Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 26(5):1150\u20131160. https:\/\/doi.org\/10.1681\/ASN.2014040325","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10318_CR26","first-page":"61","volume":"29","author":"S Shafi","year":"2017","unstructured":"Shafi S, Saleem M, Anjum R, Abdullah W, Shafi T (2017) ECG abnormalities in patients with chronic kidney disease. J Ayub Med Coll Abbottabad 29(1):61\u201364","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"6","key":"10318_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jelectrocard.2016.07.020","volume":"49","author":"JW Waks","year":"2016","unstructured":"Waks JW, Tereshchenko LG, Parekh RS (2016) Electrocardiographic predictors of mortality and sudden cardiac death in patients with end stage renal disease on hemodialysis. J Electrocardiol 49(6):848\u2013854. https:\/\/doi.org\/10.1016\/j.jelectrocard.2016.07.020","journal-title":"J Electrocardiol"},{"key":"10318_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11897-018-0406-8","volume":"15","author":"M Arrigo","year":"2018","unstructured":"Arrigo M, Cipp\u00e0 PE, Mebazaa A (2018) Cardiorenal interactions revisited: how to improve heart failure outcomes in patients with chronic kidney disease. Curr Heart Fail Rep 15:307\u2013314. https:\/\/doi.org\/10.1007\/s11897-018-0406-8","journal-title":"Curr Heart Fail Rep"},{"key":"10318_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1681\/ASN.V115912","volume":"11","author":"RN Foley","year":"2000","unstructured":"Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE (2000) Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11:912\u2013916. https:\/\/doi.org\/10.1681\/ASN.V115912","journal-title":"J Am Soc Nephrol"},{"key":"10318_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijcard.2020.03.002","volume":"306","author":"L Arcari","year":"2020","unstructured":"Arcari L, Hinojar R, Engel J et al (2020) Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions\u2013comparison of uremic, hypertensive and hypertrophic cardiomyopathy. Int J Cardiol 306:102\u2013108. https:\/\/doi.org\/10.1016\/j.ijcard.2020.03.002","journal-title":"Int J Cardiol"},{"key":"10318_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ndtplus\/sfn146","author":"CW McIntyre","year":"2008","unstructured":"McIntyre CW, John SG, Jefferies HJ (2008) Advances in the cardiovascular assessment of patients with chronic kidney disease. Oxford University Press. https:\/\/doi.org\/10.1093\/ndtplus\/sfn146","journal-title":"Oxford University Press"},{"issue":"3","key":"10318_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/RTI.0000000000000327","volume":"33","author":"JMC Lau","year":"2018","unstructured":"Lau JMC, Raptis DA, Laforest R et al (2018) Cardiac positron emission tomography-magnetic resonance imaging: current status and future directions. J Thorac Imaging 33(3):139\u2013146. https:\/\/doi.org\/10.1097\/RTI.0000000000000327","journal-title":"J Thorac Imaging"},{"issue":"5","key":"10318_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.xkme.2020.05.010","volume":"2","author":"J Kott","year":"2020","unstructured":"Kott J, Reichek N, Butler J, Arbeit L, Mallipattu SK (2020) Cardiac imaging in dialysis patients. Kidney Med 2(5):629\u2013638. https:\/\/doi.org\/10.1016\/j.xkme.2020.05.010","journal-title":"Kidney Med"},{"issue":"4","key":"10318_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1053\/j.ajkd.2016.03.418","volume":"68","author":"SV Badve","year":"2016","unstructured":"Badve SV, Palmer SC, Strippoli GFM et al (2016) The validity of left ventricular mass as a surrogate end point for all-cause and cardiovascular mortality outcomes in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis 68(4):554\u2013563. https:\/\/doi.org\/10.1053\/j.ajkd.2016.03.418","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"10318_CR35","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1161\/CIRCULATIONAHA.106.674911","volume":"115","author":"AA Shiozaki","year":"2007","unstructured":"Shiozaki AA, Santos TS, Artega E, Rochitte CE (2007) Myocardial delayed enhancement by computed tomography in hypertrophic cardiomyopathy. Circulation 115(17):e430\u2013e431. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.674911","journal-title":"Circulation"},{"issue":"4","key":"10318_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrneph.2014.243","volume":"11","author":"DY Chiu","year":"2015","unstructured":"Chiu DY, Green D, Abidin N, Sinha S, Kalra PA (2015) Cardiac imaging in patients with chronic kidney disease. Nat Rev Nephrol 11(4):207\u2013220. https:\/\/doi.org\/10.1038\/nrneph.2014.243","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10318_CR37","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1681\/ASN.2015030301","volume":"27","author":"NR Shah","year":"2016","unstructured":"Shah NR, Charytan DM, Murthy VL et al (2016) Prognostic value of coronary flow reserve in patients with dialysis-dependent ESRD. J Am Soc Nephrol 27(6):1823\u20131829. https:\/\/doi.org\/10.1681\/ASN.2015030301","journal-title":"J Am Soc Nephrol"},{"key":"10318_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijcard.2019.06.007","volume":"293","author":"MK Hayer","year":"2019","unstructured":"Hayer MK, Radhakrishnan A, Price AM et al (2019) Early effects of kidney transplantation on the heart: a cardiac magnetic resonance multi-parametric study. Int J Cardiol 293:272\u2013277. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.007","journal-title":"Int J Cardiol"},{"key":"10318_CR39","doi-asserted-by":"publisher","unstructured":"Arcari L, Camastra G, Ciolina F, Danti M, Cacciotti L (2022) T1 and T2 mapping in uremic cardiomyopathy: an update. Card Fail Rev 8:e02. https:\/\/doi.org\/10.15420\/cfr.2021.19","DOI":"10.15420\/cfr.2021.19"},{"issue":"11","key":"10318_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4330\/wjc.v10.i11.210","volume":"10","author":"D Muser","year":"2018","unstructured":"Muser D, Castro SA, Santangeli P, Nucifora G (2018) Clinical applications of feature-tracking cardiac magnetic resonance imaging. World J Cardiol 10(11):210\u2013221. https:\/\/doi.org\/10.4330\/wjc.v10.i11.210","journal-title":"World J Cardiol"},{"issue":"10","key":"10318_CR41","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1681\/ASN.2013070734","volume":"25","author":"R Kramann","year":"2014","unstructured":"Kramann R, Erpenbeck J, Schneider RK et al (2014) Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol 25(10):2351\u20132365. https:\/\/doi.org\/10.1681\/ASN.2013070734","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10318_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4330\/wjc.v14.i4.239","volume":"14","author":"MF Carrasco-Ruiz","year":"2022","unstructured":"Carrasco-Ruiz MF, Ruiz-Rivera A, Soriano-Urs\u00faa MA et al (2022) Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism. World J Cardiol 14(4):239\u2013249. https:\/\/doi.org\/10.4330\/wjc.v14.i4.239","journal-title":"World J Cardiol"},{"issue":"2","key":"10318_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","volume":"51","author":"NJ Brown","year":"2008","unstructured":"Brown NJ (2008) Aldosterone and vascular inflammation. Hypertension 51(2):161\u2013167. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.095489","journal-title":"Hypertension"},{"issue":"2","key":"10318_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0735-1097(00)01158-X","volume":"37","author":"G Cice","year":"2001","unstructured":"Cice G, Ferrara L, Di Benedetto A et al (2001) Dilated cardiomyopathy in dialysis patients\u2013beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 37(2):407\u2013411. https:\/\/doi.org\/10.1016\/S0735-1097(00)01158-X","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10318_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","volume":"54","author":"NC Edwards","year":"2009","unstructured":"Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54(6):505\u2013512. https:\/\/doi.org\/10.1016\/j.jacc.2009.03.066","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10318_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1751-7133.2011.00214.x","volume":"17","author":"SM Adhyapak","year":"2011","unstructured":"Adhyapak SM, Iyengar SS (2011) Characteristics of a subset of patients with reversible systolic dysfunction in chronic kidney disease. Congest Heart Fail 17(3):120\u2013126. https:\/\/doi.org\/10.1111\/j.1751-7133.2011.00214.x","journal-title":"Congest Heart Fail"},{"issue":"1","key":"10318_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000369588","volume":"5","author":"S Lai","year":"2015","unstructured":"Lai S, Molfino A, Russo GE et al (2015) Cardiac, inflammatory and metabolic parameters: hemodialysis versus peritoneal dialysis. Cardiorenal Med 5(1):20\u201330. https:\/\/doi.org\/10.1159\/000369588","journal-title":"Cardiorenal Med"},{"issue":"7","key":"10318_CR48","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jacc.2004.11.061","volume":"45","author":"RK Wali","year":"2005","unstructured":"Wali RK, Wang GS, Gottlieb SS et al (2005) Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 45(7):1051\u20131060. https:\/\/doi.org\/10.1016\/j.jacc.2004.11.061","journal-title":"J Am Coll Cardiol"},{"key":"10318_CR49","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147-239. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019","journal-title":"J Am Coll Cardiol"},{"key":"10318_CR50","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/eurjhf\/hfp041","volume":"11","author":"T Jaarsma","year":"2009","unstructured":"Jaarsma T, Beattie JM, Ryder M et al (2009) Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11:433\u2013443. https:\/\/doi.org\/10.1093\/eurjhf\/hfp041","journal-title":"Eur J Heart Fail"},{"key":"10318_CR51","doi-asserted-by":"publisher","unstructured":"Ma D, Mandour AS, Elfadadny A et al (2022) Changes in cardiac function during the development of uremic cardiomyopathy and the effect of salvianolic acid B administration in a rat model. Front Vet Sci 9:905759. https:\/\/doi.org\/10.3389\/fvets.2022.905759","DOI":"10.3389\/fvets.2022.905759"},{"issue":"21","key":"10318_CR52","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, for TREAT Investigators, et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019\u20132032. https:\/\/doi.org\/10.1056\/NEJMoa0907845","journal-title":"N Engl J Med"},{"issue":"2","key":"10318_CR53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000183125","volume":"36","author":"R McGonigle","year":"1984","unstructured":"McGonigle R, Fowler M, Timmis A, Weston M, Parsons V (1984) Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 36(2):94\u2013100. https:\/\/doi.org\/10.1159\/000183125","journal-title":"Nephron"},{"issue":"5","key":"10318_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, for PIVOTAL Investigators and Committees, et al (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447\u2013458. https:\/\/doi.org\/10.1056\/NEJMoa1810742","journal-title":"N Engl J Med"},{"issue":"7","key":"10318_CR55","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1681\/ASN.2020010081","volume":"31","author":"JF Bao","year":"2020","unstructured":"Bao JF, Hu PP, She QY, Li A (2020) A land of controversy: fibroblast growth factor-23 and uremic cardiac hypertrophy. J Am Soc Nephrol 31(7):1423\u20131434. https:\/\/doi.org\/10.1681\/ASN.2020010081","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10318_CR56","doi-asserted-by":"publisher","first-page":"11148","DOI":"10.1038\/s41598-019-46755-y","volume":"9","author":"BY Hu","year":"2019","unstructured":"Hu BY, Wang J, Yang ZG et al (2019) Cardiac magnetic resonance feature tracking for quantifying right ventricular deformation in type 2 diabetes mellitus patients. Sci Rep 9(1):11148. https:\/\/doi.org\/10.1038\/s41598-019-46755-y","journal-title":"Sci Rep"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10318-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10318-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T19:08:21Z","timestamp":1691176101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10318-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["10318"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10318-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"26 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Hiroaki Hiraiwa received lecture fees from Kowa Co. Ltd., Bayer Pharmaceutical Co. Ltd., and Daiichi-Sankyo Co. Ltd. Takahiro Okumura received research grants from Ono Pharmaceutical Co. Ltd., Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Amgen Astellas BioPharma K.K., Pfizer Japan Inc., Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. Takahiro Okumura received lecture fees from Ono Pharmaceutical Co. Ltd., Otsuka Pharma Ltd., Novartis Pharma K.K., and AstraZeneca K.K. Toyoaki Murohara received an unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma Inc., Daiichi-Sankyo Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Kowa Co. Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis K.K., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. All other authors declare that they have no relationships with the industry relevant to the contents of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}